» Articles » PMID: 29472314

Cysteine Modifiers Suggest an Allosteric Inhibitory Site on the CAL PDZ Domain

Overview
Journal Biosci Rep
Specialty Cell Biology
Date 2018 Feb 24
PMID 29472314
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Protein-protein interactions have become attractive targets for both experimental and therapeutic interventions. The PSD-95/Dlg1/ZO-1 (PDZ) domain is found in a large family of eukaryotic scaffold proteins that plays important roles in intracellular trafficking and localization of many target proteins. Here, we seek inhibitors of the PDZ protein that facilitates post-endocytic degradation of the cystic fibrosis (CF) transmembrane conductance regulator (CFTR): the CFTR-associated ligand (CAL). We develop and validate biochemical screens and identify methyl-3,4-dephostatin (MD) and its analog ethyl-3,4-dephostatin (ED) as CAL PDZ inhibitors. Depending on conditions, MD can bind either covalently or non-covalently. Crystallographic and NMR data confirm that MD attacks a pocket at a site distinct from the canonical peptide-binding groove, and suggests an allosteric connection between target residue Cys and the conserved Leu in the GLGI motif. MD and ED thus appear to represent the first examples of small-molecule allosteric regulation of PDZ:peptide affinity. Their mechanism of action may exploit the known conformational plasticity of the PDZ domains and suggests that allosteric modulation may represent a strategy for targeting of this family of protein-protein binding modules.

Citing Articles

Cell type-specific regulation of CFTR trafficking-on the verge of progress.

Farinha C, Santos L, Ferreira J Front Cell Dev Biol. 2024; 12:1338892.

PMID: 38505263 PMC: 10949533. DOI: 10.3389/fcell.2024.1338892.


Tryptophan mutations in G3BP1 tune the stability of a cellular signaling hub by weakening transient interactions with Caprin1 and USP10.

Sheehan C, Hampton T, Madden D J Biol Chem. 2022; 298(12):102552.

PMID: 36183834 PMC: 9723946. DOI: 10.1016/j.jbc.2022.102552.


Highway to Cell: Selection of the Best Cell-Penetrating Peptide to Internalize the CFTR-Stabilizing iCAL36 Peptide.

Seisel Q, Lakumpa I, Josse E, Vives E, Varilh J, Taulan-Cadars M Pharmaceutics. 2022; 14(4).

PMID: 35456644 PMC: 9032934. DOI: 10.3390/pharmaceutics14040808.


Proteostasis Regulators in Cystic Fibrosis: Current Development and Future Perspectives.

Brusa I, Sondo E, Falchi F, Pedemonte N, Roberti M, Cavalli A J Med Chem. 2022; 65(7):5212-5243.

PMID: 35377645 PMC: 9014417. DOI: 10.1021/acs.jmedchem.1c01897.


Cyclic Peptidyl Inhibitors against CAL/CFTR Interaction for Treatment of Cystic Fibrosis.

Dougherty P, Wellmerling J, Koley A, Lukowski J, Hummon A, Cormet-Boyaka E J Med Chem. 2020; 63(24):15773-15784.

PMID: 33314931 PMC: 8011814. DOI: 10.1021/acs.jmedchem.0c01528.


References
1.
Lockless S, Ranganathan R . Evolutionarily conserved pathways of energetic connectivity in protein families. Science. 1999; 286(5438):295-9. DOI: 10.1126/science.286.5438.295. View

2.
Schweigert N, Zehnder A, Eggen R . Chemical properties of catechols and their molecular modes of toxic action in cells, from microorganisms to mammals. Environ Microbiol. 2001; 3(2):81-91. DOI: 10.1046/j.1462-2920.2001.00176.x. View

3.
Fujii N, Haresco J, Novak K, Stokoe D, Kuntz I, Guy R . A selective irreversible inhibitor targeting a PDZ protein interaction domain. J Am Chem Soc. 2003; 125(40):12074-5. DOI: 10.1021/ja035540l. View

4.
Fuentes E, Der C, Lee A . Ligand-dependent dynamics and intramolecular signaling in a PDZ domain. J Mol Biol. 2003; 335(4):1105-15. DOI: 10.1016/j.jmb.2003.11.010. View

5.
Arkin M, Wells J . Small-molecule inhibitors of protein-protein interactions: progressing towards the dream. Nat Rev Drug Discov. 2004; 3(4):301-17. DOI: 10.1038/nrd1343. View